Enzo Biochem Inc
ENZBDelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000316253
Enzo Biochem Inc was delisted in 2025; its insiders filed their last Form 4 on Aug 20, 2025; 41 institutions reported holding it in 13F filings for Q1 2025, worth $4.96M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 41
- Q1 2025, −3 vs. previous quarter
- 13F value
- $4.96M
- Reported value at the end of Q1 2025
- Superinvestors holding
- 0
- At the end of Q1 2025
Superinvestors holding ENZB, Q1 2025
No superinvestor reported holding ENZB at the end of Q1 2025.
Latest insider trades
Open-market purchases and sales by Enzo Biochem Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2023 (view filing)9:41 PM ET | Feb 10-13 | 3 days | Wolf James G.Other: 10% owner until 2/13/2023 | PPurchaseCommon Stock, $0.01 par value | +10.0K | $1.29 | +$12.9K | +0.2%4.10M after | 2 lots |
| Feb 13, 2023 (view filing)9:41 PM ET | Feb 13 | Same day | Wolf James G.Other: 10% owner until 2/13/2023 | PPurchaseCommon Stock, $0.01 par value | +5.00K | $1.29 | +$6.45K | +4.5%115.0K after | |
| Feb 13, 2023 (view filing)9:41 PM ET | Feb 13 | Same day | Wolf James G.Other: 10% owner until 2/13/2023 | SSaleCommon Stock, $0.01 par value | −107.4K | $0.0008 | −$84.06 | –0 after | Derivative2 lots |
| Feb 13, 2023 (view filing)9:41 PM ET | Feb 13 | Same day | Wolf James G.Other: 10% owner until 2/13/2023 | SSaleCommon Stock, $0.01 par value | +107.4K | $0.0109 | +$1.17K | –2.16K after | Derivative2 lots |
| Jan 30, 2023 (view filing) | Jan 27 | 3 days | Wolf James G.10% Owner | PPurchaseCommon Stock, $0.01 par value | +11.8K | $1.40 | +$16.5K | +0.3%4.09M after | |
| Jan 19, 2023 (view filing)2:37 PM ET | Oct 31-Nov 1, 2022 | 80 daysLate | Wolf James G.10% Owner | PPurchaseCommon Stock, $0.01 par value | +23.0K | $2.15 | +$49.4K | +5.8%418.5K after | 3 lots |
| Jan 19, 2023 (view filing)2:37 PM ET | Nov 1-3, 2022 | 79 daysLate | Wolf James G.10% Owner | PPurchaseCommon Stock, $0.01 par value | +154.0K | $0.0048 | +$738 | –1.70K after | Derivative5 lots |
| Jan 19, 2023 (view filing)2:37 PM ET | Nov 1-Dec 15, 2022 | 79 daysLate | Wolf James G.10% Owner | SSaleCommon Stock, $0.01 par value | +205.1K | $0.0082 | +$1.67K | –1.75K after | Derivative9 lots |
| Jan 19, 2023 (view filing)2:37 PM ET | Dec 5-30, 2022 | 45 daysLate | Wolf James G.10% Owner | SSaleCommon Stock, $0.01 par value | −70.6K | $0.0018 | −$128.15 | –3.24K after | Derivative4 lots |
| Nov 28, 2022 (view filing) | Nov 23 | 5 days | Erfanian HamidChief Executive Officer | PPurchaseCommon Stock, $0.01 Par Value | +100.0K | $1.97 | +$197.0K | +36.4%374.6K after |
Top 10 13F holders, Q1 2025
The largest institutional positions in Enzo Biochem Inc at the end of Q1 2025; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Harbert Fund Advisors, Inc. | 5,175,913 | $1.92M | 2.22% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 2,082,229 | $770.4K | 0.00% | −285,314−12.1% | Reduced |
| Vanguard Group Inc | 1,859,002 | $687.8K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 957,775 | $354.4K | 0.00% | −2,064−0.2% | Reduced |
| Mink Brook Asset Management LLC | 807,899 | $298.9K | 0.31% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 431,042 | $159.5K | 0.00% | +63,949+17.4% | Added |
| Wittenberg Investment Management, Inc. | 274,095 | $101.4K | 0.05% | +86,558+46.2% | Added |
| RBF Capital, LLC | 250,359 | $92.6K | 0.01% | 00.0% | Unchanged |
| Citadel Advisors LLC | 210,877 | $78.0K | 0.00% | +164,921+358.9% | Added |
| State Street Corp | 168,881 | $62.5K | 0.00% | 00.0% | Unchanged |